Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Grapples To Get A Handle On Reporting Mechanisms For Adverse Drug Reactions

This article was originally published in The Pink Sheet Daily

Executive Summary

As far back as 2004, the Measures on Administration of Reporting and Monitoring of Adverse Drug Reactions were promulgated. By 2007, there were 400 cases per million people reported.

You may also be interested in...



Safety Of Traditional Chinese Medicine Injections Questioned Following Three Deaths

SHANGHAI - Three deaths caused by adverse drug reactions allegedly linked to use of herbal injection Shuanghuanglian have raised wider concerns over the safety of herbal injections in China

China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices

BEIJING - An array of regulatory and legal changes covering pharmaceuticals and medical devices in China is likely to be launched or broadened this year, including new GMP guidelines, as the country aims to upgrade supervision of the entire health care sector, according to a leading Chinese lawyer in the area of life sciences-related issues and legislation

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel